Your session is about to expire
← Back to Search
AYA-RISE Program for Cancer Syndromes (AYA-RISE Trial)
AYA-RISE Trial Summary
This trial is testing whether using a chatbot and online portal for cancer risk information helps improve communication and decision-making.
AYA-RISE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAYA-RISE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AYA-RISE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am aged 12-24, have a cancer risk syndrome, speak English, and am not currently undergoing cancer treatment.I am aged 12-24, have a cancer risk syndrome, speak English, and am not on active cancer therapy.I am an English-speaking healthcare provider for adolescents and young adults with cancer risk syndromes.I am 12-24, have a cancer risk syndrome, speak English, treated at Dana-Farber, not on active cancer therapy, and didn't do a stakeholder interview.
- Group 1: Aim 2- Genetic Counseling with AYA-RISE
- Group 2: Aim 3 Semi-structured interviews
- Group 3: Aim 2-Genetic Counseling
- Group 4: Aim 1-Part 2
- Group 5: Aim 1-Part 1 Stakeholder Interview
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent has participation in the trial been successful?
"Affirmative. According to the data on clinicaltrials.gov, this medical experiment is currently enrolling patients and was initially posted on March 1st 2021. It has been updated most recently on April 25th 2022 and seeks 354 participants at 5 different sites across the country."
Could I potentially participate in this scientific investigation?
"This clinical study seeks to enroll 354 youths aged 12-24, who are living with Syndrome. Other requirements include that they must not be receiving active cancer treatment and possess adequate cognitive function (as indicated by a NeuroQOL score of 30 or more). Additionally, patients may come from any of the participating medical sites or attend the LiFraumeni Syndrome Association's Youth Conference."
How many sites are in operation for this trial?
"The study is welcoming enrolment from participants at University of Utah, Huntsman Cancer Institute in Salt Lake City, Boston Children's Hospital in Chicago, and the University of Chicago in Atlanta. Simultaneously there are five additional medical centres currently participating."
Does this investigation accept participants above the age of 25?
"Patients between the ages of 12 and 24 years old may join this trial."
What is the enrollment status of this trial?
"Affirmative. Indications on clinicaltrials.gov point to this trial as actively seeking out individuals for enrollment. The study was first posted on March 1st 2021 and revised most recently on April 25th 2022, with the goal of including 354 patients across 5 different sites."
Share this study with friends
Copy Link
Messenger